Table 1 Clinical characteristics of study participants at the beginning and end of the follow-up period
Patient number | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
Sex (M-male, F-female) | M | M | M | M | M |
Age at the onset of follow-up (years) | 18 | 23 | 34 | 26 | 31 |
Diabetes duration at the onset of follow-up (years) | 7 | 13 | 12 | 9 | 18 |
Sport type | MMA | Kick-boxing | Kick-boxing | MMA | MMA |
Duration of sport practice (years) | 4 | 7 | 12 | 9 | 14 |
Diabetes treatment method (MDI/CSII) | MDI | CSII | MDI | CSII | MDI |
Duration of the follow-up (months) | 25 | 38 | 24 | 36 | 35 |
HbA1c at the beginning of the follow-up (%, mmol/mol) | 8.4 (68) | 8.2 (66) | 8.6 (70) | 7.6 (60) | 7.9 (63) |
HbA1c at the end of the follow-up | 7.8 (62) | 7.6 (60) | 7.4 (57) | 7.3 (56) | 7.1 (54) |
Mean glucose level from glucometer memory at the beginning of the follow-up (mg/dL) with standard deviation (mg/dL) | 198 ± 84 | 189 ± 92 | 212 ± 89 | 174 ± 76 | 182 ± 81 |
Mean glucose level from glucometer memory at the end of the follow-up (mg/dL) with standard deviation (mg/dL) | 179 ± 62 | 171 ± 68 | 163 ± 64 | 152 ± 52 | 139 ± 63 |
Number of symptomatic hypoglycemia/week at the beginning of the follow-up (4Â weeks data) | 8.1 | 10.1 | 8.7 | 6.2 | 12.3 |
Number of symptomatic hypoglycemia/week at the end of the follow-up (4Â weeks data) | 4.2 | 6.0 | 2.1 | 4.2 | 6.1 |
Number of hospitalizations due to metabolic decompensation (severe hypoglycemia or acidosis) during the 2Â years prior to the beginning of follow-up | 0 | 3 | 1 | 0 | 1 |
Number of hospitalizations due to metabolic decompensation (severe hypoglycemia or acidosis) during follow-up | 0 | 0 | 0 | 0 | 0 |
Mean number of BG measurements/day at the beginning of follow-up | 3.1 | 4.2 | 2.9 | 5.4 | 6.1 |
Mean number of BG measurements/day at the end of follow-up | 10.2 | 9.1 | 8.1 | 9.3 | 12.4 |
Total daily insulin dose/kg at the beginning of follow-up (IU/kg) | 0.71 | 0.57 | 0.68 | 0.53 | 0.55 |
Total daily insulin dose at the end of follow-up (IU/kg) | 0.55 | 0.53 | 0.51 | 0.52 | 0.47 |
% Prandial insulin at the beginning of follow-up | 46 | 53 | 58 | 62 | 66 |
% of total daily insulin amount given as prandial doses at the end of the follow-up | 56 | 58 | 62 | 66 | 68 |